MedImmune Deal Validates Inovio's Cancer Tech

Barron'sMedImmune Deal Validates Inovio's Cancer TechBarron'sThis agreement provides validation to Inovio's technology of generating cancer-specific killer T cells in vivo. In the wake of this update, we reiterate our Buy rating on Inovio and 12-month target price of $17. Our target is derived from a firm value ...AstraZeneca's Contribution To Cancer EradicationScience TimesCancer eradication, thanks to AstraZenecaMorning TickerAstraZeneca bags another cancer drug deal, this time with InovioReutersall 128 news articles »

Share this post